127724-75-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-7,8-dihydroquinolin-5(6H)-one is used as a building block for the synthesis of various organic compounds and pharmaceutical agents due to its interesting biological activities.
Used in Antimicrobial Applications:
3-Chloro-7,8-dihydroquinolin-5(6H)-one is used as an antimicrobial agent for its potential to combat various microorganisms, contributing to the development of new treatments for infectious diseases.
Used in Anticancer Applications:
3-Chloro-7,8-dihydroquinolin-5(6H)-one is used as an anticancer agent, leveraging its biological activities to target and inhibit the growth of cancer cells, potentially leading to novel therapeutic strategies for cancer treatment.
Used in Medicinal Chemistry Research:
3-Chloro-7,8-dihydroquinolin-5(6H)-one is used as a subject of study in medicinal chemistry research to explore its potential use in the treatment of various diseases and conditions, furthering our understanding of its therapeutic potential.

InChI:InChI=1/C9H8ClNO/c10-6-4-7-8(11-5-6)2-1-3-9(7)12/h4-5H,1-3H2

Upstream product

• 137628-23-0 3-bromo-5-chloro-2-<3-<(N,N-dimethylamino)carbonyl>propyl>pyridine 
• 504-02-9 1,3-cylohexanedione 
• 5220-49-5 3-amino-cyclohex-2-enone 
• 1162663-26-4 2-bromo-3-chloroacrylaldehyde 
• 137628-22-9 3-bromo-5-chloro-2-(3-carboxypropyl)pyridine 
• 137628-19-4 3-bromo-5-chloro-2-(4-hydroxybutyl)pyridine 
• 137628-18-3 3-bromo-5-chloro-2-<4-<(tetrahydro-2H-pyran-2-yl)oxy>butyl>pyridine 

Relevant academic research and scientific papers

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.

A general preparation of pyridines and pyridones via the annulation of ketones and esters

A general preparation of pyridines 4a-f from stabilized ketones 3a-c and aryl ketones 3d-f is described. The annulation of stabilized esters 3g,h gives access to the corresponding 2-pyridones 4g,h. The annulation reactions proceed in fair to excellent yie

3-bromo-5-chloro-pyridines used as intermediates in the synthesis of azatetralones

Compounds of the formula STR1 wherein R1 is hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, C1 to C4 alkoxy, C1 to C4 alkylthio or C1 to C6 alkyl and R2 is a group of the formula STR2 wherein R3 is hydrogen or C1 to C6 alkyl, R4 is --CH=C2, --CH2 --YR5, or --COR6, R5 is hydrogen or an acid labile alcohol protecting group, Y is oxygen or sulfur, and R6 is --NR7 R8 or --OR9 wherein R7, R8 and R9 are independently selected from hydrogen or C1 to C6 alkyl, or an alkaline or alkaline earth metal salt thereof, which are intermediates in the preparation of hydantoin aldose reductase inhibitors and methods of preparing these intermediates.

Novel resolution process for racemic spiro-hydantoins

A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S) or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric uredio compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diastereomers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C1 -C4), followed by acidification, whereupon the desired optical isomer is obtained. The final products so obtained, such as (4S)-(+)-6-fluoro-2,3-dihydro-spiro[4H-1-benzopyran-4,4'-imidazolidine]-2', 5'-dione (sorbinil) and (5'S)-3'-chloro-5', 6', 7', 8'-tetra-hydro-spiro[imidazolidine-4,5'-quinoline]-2,5-dione, are known to be useful in preventing or alleviating certain chronic diabetic complications. The aforementioned diastereomeric uredio intermediates are novel compounds.